Team:UIUC-Illinois/Project/Future/AssemblyLine
From 2012.igem.org
Line 41: | Line 41: | ||
<br/> | <br/> | ||
<p> | <p> | ||
- | Earlier this year, research at the Kee-Hong Kim lab of Purdue University had preliminary evidence showing that a | + | Earlier this year, research at the Kee-Hong Kim lab of Purdue University had preliminary evidence showing that a trans-stilbene compound, Piceatannol, had an ability to inhibit the development of human adipose cells. The mechanism is based around the idea that Piceatannol interacts with a preadipocyte's (immature fat cell) insulin receptors in such a way that surpresses it's growth into a mature adipose cell. Such a compound is a metabolite of a prime candidate for biochemical research, Resveratrol, which differs from Piceatannol only by an extra hydroxl group housed on one of its aromatic rings. |
<br/><br/> | <br/><br/> | ||
Piceatannol is currently very costly to synthesize. On the advent of such a discovery, we felt that if we were to engineer a pathway to optimize the production of Piceatannol from cheaper substrates through the utilization of our PUF and RNA scaffold projects, we could show the versatility of our PUF toolkit working with an RNA scaffold. | Piceatannol is currently very costly to synthesize. On the advent of such a discovery, we felt that if we were to engineer a pathway to optimize the production of Piceatannol from cheaper substrates through the utilization of our PUF and RNA scaffold projects, we could show the versatility of our PUF toolkit working with an RNA scaffold. | ||
Line 53: | Line 53: | ||
</ul> | </ul> | ||
</p> | </p> | ||
- | + | <br/> | |
<div id="assembly0" style="display:none"> | <div id="assembly0" style="display:none"> | ||
<center><h2>Enzymatic Assembly Line Overview</h2></center> | <center><h2>Enzymatic Assembly Line Overview</h2></center> |
Revision as of 05:43, 2 October 2012